- (original) A system for the production of recombinant N-glycosylated target
  proteins, the system comprising a prokaryotic organism into which is introduced a
  genetic information encoding for a metabolic apparatus capable of carrying out the
  requested N-glycosylation of the target protein, wherein said prokaryotic organism
  also contains the genetic information required for the expression of one or more
  recombinant target proteins.
- (original) The system of claim 1, wherein the metabolic apparatus comprises
  specific glycosyltransferases for the assembly of the oligosaccharide on a lipid
  carrier and an OTase that covalently links this oligosaccharide to specific residues
  of the desired target protein.
- (amended) The system of ene of claim[[s]] 1 er 2, wherein the prokaryotic organism is Escherichia coli.
- 4. (amended) The system of one of claim[[s]] 2 or 3, wherein the prokaryotic organism is producing N-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
- 5. (original) A method of producing recombinant N-glycosylated target proteins, the method comprising the introduction of a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein into a prokaryotic organism, wherein also the genetic information required for the expression of one or more recombinant target proteins is introduced into said prokaryotic organism.
- 6. (original) The method of claim 5, wherein the metabolic apparatus comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase, the OTase covalently linking this oligosaccharide to specific residues of the desired target protein.

- 7. (original) The method of one of claims 5 or 6, wherein the prokaryotic organism is Escherichia coli.
- 8. (amended) The method of one of claim[[s]] 6 or 7, wherein by selection of specific glycosyltranserases the prokaryotic organism is producing N-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
- (amended) Utilization of the system of one of claim[[s]] I [[-4]] or the method of
  one of claims 5-8 for the production of target proteins for the development of
  medicaments or for the production of medicaments for the treatment of humans or
  animals or plant.
- (amended) Proteins for nutrition and/or pharmaceutical purposes, produced with the system of one of claims 1 [[-4]] or according to the method of one of claims 5 to 8.
- 11. (amended) Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the system of one of claim[[s]] 1[[-4]] or according to the method of one of claims 5 to 8.
- (amended) Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the system of one of claim[[s]]-1-4-or eccording to the method-of one of claims-5-8.
- 13. (amended) Utilization of a medicament produced with the system of one of claim[[s]] 1[[-4]] or according to the method of one of claims 5-8 for the therapy of human or animal or plant diseases.
- 14. (new) The system of claim 2, wherein the prokaryotic organism is Escherichia coli.

- 15. (new) The system of claim 3, wherein the prokaryotic organism is producing Nglycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
- 16. (new) Utilization of the method of claim 5 for the production of target proteins for the development of medicaments or for the production of medicaments for the treatment of humans or animals or plant.
- 17. (new) Proteins for nutrition and/or pharmaceutical purposes, produced with the method of claim 5.
- 18. (new) Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the method of claim 5.
- 19. (new) Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the method of claim 5.
- 20. (new) Utilization of a medicament produced with the method of claim 5 for the therapy of human or animal or plant diseases.